Main Menu

Prevail Therapeutics Inc.

(NASDAQ GS: PRVL)

Rigrodsky Law, P.A. is investigating Prevail Therapeutics Inc. (“Prevail”) regarding possible breaches of fiduciary duties and other violations of law related to Previal's agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Prevail’s shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.

 

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 01/21/2021


* Indicates a required field.

Back to Page